GE's Genomic Future

GE’s Genomic Future
On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the more far-reaching consequences of the deal puts GE on the cutting edge of how new knowledge about genetics is used to treat patients. The deal could put General Electric in direct competition with diagnostic and drug firms such as Roche and Abbott Laboratories.

Comments are closed.